Wedbush Boosts Target on Outperform-Rated Oncothyreon (ONTY) to $31 Ahead of STIMUVAX Phase III Data
Go back to Wedbush Boosts Target on Outperform-Rated Oncothyreon (ONTY) to $31 Ahead of STIMUVAX Phase III Data| ONCOTHYREON (NASDAQ: ONTY) | Delayed: 1.21 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.21 | 52 Week High | $4.11 | |||
| Open | $0.01 | 52 Week Low | $0.90 | |||
| Day High | $1.21 | P/E | N/A | |||
| Day Low | $1.21 | EPS | $-0.93 | |||
| Volume | 824,689 | |||||
